Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors

Diabetes, Obesity and Metabolism

Volumn 21, Issue 2, 2019, Pages 434-438

  Dave, Chintan V ^a   Schneeweiss, Sebastian ^a   Patorno, Elisabetta ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

antidiabetic drug; pharmacoepidemiology; SGLT2 inhibitor; type 2 diabetes

Indexed keywords

ALOGLIPTIN; ANTIBIOTIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; ESTROGEN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LINAGLIPTIN; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; STEROID; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BALANITIS; BALANOPOSTHITIS; CANDIDIASIS; CLINICAL OUTCOME; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENITAL TRACT INFECTION; HIGH RISK PATIENT; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHIMOSIS; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; UNITED STATES; VAGINITIS; VULVOVAGINITIS; YOUNG ADULT; ADVERSE EVENT; AGED; INSURANCE; RISK FACTOR;

ADULT; AGED; CANDIDIASIS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; REPRODUCTIVE TRACT INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; UNITED STATES;

EID: 85054851005     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13531     Document Type: Article

References (20)

1. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med. 2015;66:255-270.
2. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes a systematic review and meta-analysis. Ann Intern Med. 2013;159:262-274.
3. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.
4. Patorno E, Goldfine AB, Schneeweiss S, et al. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ. 2018;360:k119.
5. Geerlings SE, Brouwer EC, Gaastra W, Verhoef J, Hoepelman AI. Effect of glucose and pH on uropathogenic and non-uropathogenic Escherichia coli: studies with urine from diabetic and non-diabetic individuals. J Med Microbiol. 1999;48:535-539.
6. Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19:348-355.
7. Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017;7:2824.
8. Zaccardi F, Webb D, Htike Z, Youssef D, Khunti K, Davies M. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016;18:783-794.
9. Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4:411-419.
10. Jabbour S, Seufert J, Scheen A, Bailey CJ, Karup C, Langkilde AM. Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab. 2018;20:620-628.
11. Aronson R, Frias J, Goldman A, Darekar A, Lauring B, Terra SG. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes Obes Metab. 2018;20:1453-1460.
12. Fioretto P, Del Prato S, Buse JB, et al. Efficacy and safety of Dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE study. Diabetes Obes Metab. 2018 [published online ahead of print]. https://doi.org/10.1111/dom.13413.
13. Li D, Shi W, Wang T, Tang H. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2018;20:1972-1976.
14. Inagaki N, Si H, Kaku K, et al. Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2018;20:812-820.
15. Grigoriou O, Baka S, Makrakis E, Hassiakos D, Kapparos G, Kouskouni E. Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol. 2006;126:121-125.
16. Lisboa C, Santos A, Dias C, Azevedo F, Pina-Vaz C, Rodrigues A. Candida balanitis: risk factors. J Eur Acad Dermatol Venereol. 2010;24:820-826.
17. Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103:373-381.
18. Wang S, Verpillat P, Rassen J, Patrick A, Garry E, Bartels D. Transparency and reproducibility of observational cohort studies using large healthcare databases. Clin Pharmacol Ther. 2016;99:325-332.
19. Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: epidemiology, microbiology and risk factors. Crit Rev Microbiol. 2016;42:905-927.
20. Patorno E, Gopalakrishnan C, Franklin JM, et al. Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records. Diabetes Obes Metab. 2018;20:974-984.